Lifetime Management in Low- And Intermediate-Risk TAVI: Insights on Navitor and the VANTAGE Data | M. Adamo
Don't miss M. Adamo discussing about the importance of lifetime management, minimising complications, ensuring valve durability and preserving coronary access for future interventions. Navitor™’ is presented, reviewing the VANTAGE trial with 0% moderate/severe PVL at 30 days, 97% technical success and very low mortality and stroke at one year, confirming Navitor’s safety and effectiveness in this population.
LEARN MORE:
Related Videos
Procedural tip & tricks with Navitor across all valve sizes
Transcatheter Aortic Valves Implant
1-year VANTAGE TAVI outcomes in low/intermediate-risk patients
A Defining Moment Has To Start Somewhere. Why Not With You?
Webinar for Collaborative Management of HF Patients with MR
Transcatheter tricuspid valve repair: Cases, tips and tricks
M-TEER: Best treatment strategies for FMR AND DMR
Latest evidence in patient selection for T-TEER
TRENDING TOPICS
Procedural tip & tricks with Navitor across all valve sizes
1-year VANTAGE TAVI outcomes in low/intermediate-risk patients
Transcatheter Aortic Valves Implant
